Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529

Jordan R. Kharofa, Greg Yothers, Lisa A. Kachnic, Jaffer Ajani, Joshua E. Meyer, Mark E. Augspurger, Gordon S. Okawara, Madhur K. Garg, Tracey E. Schefter, Todd A. Swanson, Desiree E. Doncals, Hyun Kim, Bassem I. Zaki, Samir Narayan, R. Jeffery Lee, Harvey J. Mamon, Michael A. Schwartz, Jennifer Moughan, Christopher H. Crane

Research output: Contribution to journalArticlepeer-review

Abstract

Novel toxicity metrics that account for all adverse event (AE) grades and the frequency of may enhance toxicity reporting in clinical trials. The Toxicity Index (TI) accounts for all AE grades and frequencies for categories of interest. We evaluate the feasibility of using the TI methodology in 2 prospective anal cancer trials and to evaluate whether more conformal radiation (using Intensity Modulated Radiation Therapy) results in improved toxicity as measured by the TI. Patients enrolled on NRG/RTOG 0529 or nonconformal RT enrolled on the 5-Fluorouracil/Mitomycin arm of NRG/RTOG 9811 were compared using the TI. Patients treated on NRG/RTOG 0529 had lower median TI compared with patients treated with nonconformal RT on NRG/RTOG 9811 for combined GI/GU/Heme/Derm events (3.935 vs 3.996, P=0.014). The TI methodology is a feasible method to assess all AEs of interest and may be useful as a composite metric for future efforts aimed at treatment de-escalation or escalation.

Original languageEnglish
Pages (from-to)534-536
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume45
Issue number12
DOIs
StatePublished - Dec 1 2022

Keywords

  • anal cancer
  • intensity modulated radiation therapy
  • toxicity index

Fingerprint

Dive into the research topics of 'Use of the Toxicity Index in Evaluating Adverse Events in Anal Cancer Trials: Analysis of RTOG 9811 and RTOG 0529'. Together they form a unique fingerprint.

Cite this